Rallybio Corp is a US-based commercial services company with a focus on ESG. With a risk rating score of 22.0, it is considered a medium risk company. Specializing in clinical stage biotechnology, Rallybio Corp is dedicated to developing therapies for severe and rare disorders. One of its key programs targets fetal and neonatal alloimmune thrombocytopenia, a rare disease causing life-threatening bleeding in babies.